NCT06999525

Brief Summary

Digestive endoscopies are performed either for diagnostic purposes (e.g. suspicion of cancer or monitoring of chronic diseases) or for therapeutic purposes (treatment of digestive haemorrhage, removal of polyps, etc.). Some endoscopies are performed under local anaesthetic, which can cause considerable anxiety in anticipation of the procedure and considerable discomfort during the procedure. Other endoscopies are performed under general anaesthetic for more extensive procedures on outpatients or inpatients. Anxiety prior to anaesthesia is likely to increase the perception of pain, increase the need for anaesthetic products and thus increase the time to complete awakening. Complementary techniques such as hypnotherapy can be used before the operation, with proven effectiveness. But these techniques require dedicated and specifically trained staff, as well as additional time. Virtual reality technologies, and in particular virtual reality headsets, allow instant immersion in a relaxing world. Therapeutic virtual reality headsets (TRVH) have been shown to be effective in reducing pre-operative anxiety and pain perception. Our hypothesis is that the use of a CRVT could reduce the consumption of anaesthetic products, reduce anxiety, improve overall satisfaction and reduce the length of outpatient hospitalisation during digestive endoscopy procedures.

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
50

participants targeted

Target at P25-P50 for not_applicable

Timeline
8mo left

Started Jul 2025

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress57%
Jul 2025Jan 2027

First Submitted

Initial submission to the registry

April 25, 2025

Completed
1 month until next milestone

First Posted

Study publicly available on registry

May 31, 2025

Completed
1 month until next milestone

Study Start

First participant enrolled

July 1, 2025

Completed
1.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2027

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2027

Last Updated

May 31, 2025

Status Verified

May 1, 2025

Enrollment Period

1.5 years

First QC Date

April 25, 2025

Last Update Submit

May 30, 2025

Conditions

Keywords

EndoscopyVirtual reality technologies

Outcome Measures

Primary Outcomes (1)

  • total propofol consumption

    To compare total propofol consumption between patients who received CRVT immersion and control patients.

    at day 1

Secondary Outcomes (4)

  • Time of awakening

    at day 1

  • patient satisfaction

    at day 1

  • post-endoscopy anxiety assessement

    at baseline and at day 1

  • Duration of hospitalization

    at day 1

Study Arms (2)

With virtual reality technologies

EXPERIMENTAL

Patients with virtual reality technologies during endoscopy procedure

Device: Therapeutic virtual reality headset (CRVT)

Without virtual reality technologies

NO INTERVENTION

Routine procedure of endoscopy

Interventions

Contribution of the use of a Therapeutic Virtual Reality Headset in the management of anxiety and discomfort in digestive endoscopy

With virtual reality technologies

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age ≥ 18 years (adult patients)
  • Affiliated with a French social security system
  • No legal protection measures (e.g., guardianship, curatorship)
  • Scheduled for outpatient digestive endoscopy (upper or lower) under general anesthesia, level 1 (excluding biliary or interventional procedures)
  • Medical indication for the endoscopic procedure established by a clinician

You may not qualify if:

  • History of epilepsy
  • Claustrophobia

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Officials

  • Thomas BAZIN, MD, PhD

    CHU Ambroise Paré, APHP, France

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Thomas BAZIN, MD, PhD

CONTACT

Paul Dessaint, MD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 25, 2025

First Posted

May 31, 2025

Study Start

July 1, 2025

Primary Completion (Estimated)

January 1, 2027

Study Completion (Estimated)

January 1, 2027

Last Updated

May 31, 2025

Record last verified: 2025-05